Elena Cleary

Elena Cleary has a strong background in the pharmaceutical industry, with a focus on the development and regulatory strategies for epilepsy treatments. Elena has held various leadership roles, including Vice President of Development and Vice President of Regulatory Pathways at UCB. In these positions, they were responsible for global development and delivery of assets for epilepsy and rare syndromes, as well as leading innovative regulatory strategies. Prior to UCB, Elena worked at Schwarz Biosciences as a Director/Senior Director of Medical Writing and at GlaxoSmithKline as a Scientist/Director of Submissions Development. Overall, Elena has extensive experience in clinical development, regulatory affairs, and life cycle management in the field of epilepsy treatment.

Elena Cleary has a strong educational background in the field of neurobiology and molecular neuropharmacology. Elena obtained a Ph.D. in Neurobiology from Loyola University Chicago Stritch School of Medicine in 1994. Prior to that, they earned a B.S. in Biology - honors from the University of Illinois Urbana-Champaign in 1987. Elena also pursued post-doctoral studies in Molecular Neuropharmacology at the University of North Carolina at Chapel Hill from 1994 to 1996. In addition to their formal education, Elena holds a certification in Regulatory Affairs (RAC) from the Regulatory Affairs Professionals Society (RAPS), obtained in 2018.